# Barrier Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/barrier-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Princeton, US
- Website: www.stiefel.com
- Total disclosed funding: $78M
- Latest round: Series C (Oct 27, 2003)
- Investors on record: 7

## About

Barrier Therapeutics is a pharmaceutical company focused on developing innovative treatments for dermatological conditions. Their expertise lies in advancing therapies that enhance skin health and improve patient outcomes.Barrier Therapeutics was founded in 2002 in Princeton, US, and operates as a subsidiary under Stiefel Laboratories. The company specializes in dermatology and raised USD 148.00 mn in an Add-on funding round led by Stiefel Laboratories, totaling USD 148.00 mn raised to date. The company had five deals, with the most recent deal occurring on April 1, 2004. The founder’s background information is not publicly available.Barrier Therapeutics primarily offers products that target various dermatological issues, addressing significant health challenges. Their product portfolio includes prescription medications that aim to improve skin health, focusing on enhancing treatment accessibility for patients through partnerships and programs that support healthcare delivery.In 2007, Barrier Therapeutics reported a revenue of USD 24.08 mn. The company's operational expenses resulted in an EBITDA of USD -55.87 mn during the same year, reflecting its financial performance as it continued to develop and market its therapeutic products.Barrier Therapeutics is focused on expanding its product line with new dermatological therapies, although specific upcoming products or launch dates have not been disclosed. The company also aims to broaden its presence in new markets, particularly targeting regions with unmet dermatological needs. The recent funding will be utilized to support these initiatives and enhance product development efforts as they continue to scale their operations following their acquisition by Stiefel Laboratories in June 2008.

## Funding rounds

- Series C, Oct 27, 2003, $32M — TL Ventures, Johnson & Johnson Innovation, Aisling Capital, JP Morgan Asset Management, MPM BioImpact, Baker-Tisch Investments, KBC Bank
- Series B, May 1, 2002, $46M — TL Ventures, Aisling Capital, JP Morgan Asset Management, Baker-Tisch Investments, KBC Bank

## Investors

- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B, Series C
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series B, Series C
- Baker-Tisch Investments — Series B, Series C
- KBC Bank — Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C